Donald B. Hawthorne Email and Phone Number
Donald B. Hawthorne work email
- Valid
- Valid
- Valid
Donald B. Hawthorne personal email
- Valid
Donald B. Hawthorne phone numbers
TWO QUESTIONSIs your executive team Getting GTM® Right so you can build your company for growth?If you will be (i) seeking new funding, (ii) pursuing corporate partnering or M&A deals, (iii) developing your portfolio of offerings; and/or (iv) seeking to improve your current operating performance during the next year - then investors, partners and customers will be scrutinizing your go-to-market (GTM) strategy. Are you ready for prime time?ONE CHALLENGEThe most common reaction I get from executives when I ask them about how confident they are that their GTM strategies are robust: "We've got it covered." I understand the comment as I said the same words during my CEO days. But here is the problem: Some 70% of products flop or fail outright while close to 100% of executives believe their companies fall in the remaining 30% category.What basis do you have for being confident your company will end up in the 30% category?I developed the GTM Readiness Self-Assessment online survey - based on my novel GTM Persuasion Framework - to allow teams to test their GTM strategy to ensure they are internally aligned before they are subjected to external diligence scrutiny.My challenge: Have your team take the survey and let's discuss the results in a PowerLab® workshop customized around your team's answers. After the workshop, all of you can (re)assess your readiness.I look forward to talking with you.Strategy. Performance. Results.®WHO I WORK WITHExecutives. Equity Investors. Boards of Directors. Bankers.WHY MEI bring a been-there, done-that operating executive mindset to my GTM consulting work. Drawing on experience in 12 C-suite roles (CEO-6, COO-2, CFO-4), I serve as a peer-level partner with CEOs and other C-suite members as well as their investors and Board members so their company can develop the robust GTM strategies that will persuade investors, corporate partners, and customers to care enough to invest or partner with their company and buy its offerings.I have worked in or with 52 companies who have ranged from startups to large companies, and from high-growth organizations to turnarounds. Most were funded by venture capital, angel, and private equity investors. I have also led GTM strategy workshops with approximately 125 startups. There is very little I have not seen.I have raised $317 million of debt and equity monies in public (IPOs, secondaries, PIPES) and private markets, closed 10 business development deals, and been involved in 5 M&A transactions.MBA, Stanford Graduate School of Business. BS, Harvey Mudd College.
Gtm® Hawthorne, Inc.
View-
PresidentGtm® Hawthorne, Inc. Apr 2018 - PresentChestnut Hill, Ma, UsMY MISSIONHelp executives whose companies have up to $100 million in revenue design go-to-market (GTM) strategies that will persuade investors, corporate partners, and customers to care enough to invest or partner with their company and buy its offerings.PROVIDING VALUE TO YOUSuccessfully navigating due diligence scrutiny in the marketplace (by customers) and in strategic transactions (by investors and corporate partners) is a must-have that enables companies to grow and deliver dominant valuation and operating performance outcomes over time.Let’s talk about how I can help you take your company to new heights.BACKGROUNDMy eclectic career path began 27 years ago when I moved from Silicon Valley to Rhode Island to honor a family commitment. The subsequent wide range of experiences gave me some unique perspectives and led to the conclusion that getting the business and human elements of GTM right was the missing link to ensuring companies could successfully build for growth. I was reminded of Steve Jobs’ words in his 2005 Stanford commencement speech: “You cannot connect the dots looking forward. You can only connect them looking backwards. You have to trust the dots will somehow connect in your future.” What got me superficially labeled as a turnaround guy over 20 years ago allowed me to become an expert at both detecting GTM blind spots and then figuring out what to do differently.I now connect the dots through my novel GTM® Persuasion Framework and GTM Readiness Self-Assessment diagnostic, which take on meaning via PowerLab® workshops. Both serve as insurance policies against the failure to Get GTM Right. The PPT below describes my unique perspective on how to develop a robust GTM strategy.With experience holding 12 C-suite roles, I bring an operating executive mindset/lens to my consulting work. 21 case study success stories are also below. -
President, Ceo & Board MemberDaktari Diagnostics Sep 2015 - Apr 2018Cambridge, Massachusetts, UsHired by Board of Directors to redirect commercial focus of point-of-care immunoassay diagnostics company, completing transition from a single diagnostic product in a declining market to development of an ultra-sensitive technology platform capable of addressing multiple large diagnostic test market opportunities. Due to cap table constraints existing at the time of my hiring, the strategy was to show proof-of-principle for the new ultra-sensitive technology platform and then sell the company. Primary accomplishments: --Developed target product profiles for three diagnostic tests: High-sensitivity cardiac troponin I (hs-cTnI), HIV viral load, and hepatitis C (HCV) core antigen (cAg) after defining unmet market need, competitive landscape, and size of addressable market for each test.--Completed initial go-to-market HCV cAg commercialization plan, incorporating results from over 80 interviews. Completed development of cartridge design suitable for commercial production, earning Merck HCV deal milestone payment. Developed new HCV antibodies that outperformed any commercially available antibodies.--Achieved clinically relevant lower limit of detection with HIV+ Ab- plasma samples, in-tube.--Achieved initial clinically relevant hs-cTnI lower limit of detection with plasma samples, in-tube.As we were making progress toward showing the proof points that were expected to generate interest in acquiring the company, the family office shareholder who was the sole funding source for the company made a strategic decision to stop investing in any private companies anywhere. -
President & CeoAdvandx, Inc. Jun 2014 - Jul 2015Woburn, Ma, UsHired by Board of Directors of infectious disease molecular diagnostics company less than three months after closing of new equity financing, with mission to lead development and implementation of new strategy necessary to achieve investors’ vision. Sold company to OpGen in July 2015. -
Founder & PresidentThe Hawthornegroup Jun 2010 - Jun 2014The HawthorneGroup (THG) was a nationwide team of Go-To-Market Specialists who delivered Value, Speed and Cost benefits to life science companies. THG served as peer-level partners to management with primary areas of expertise being in strategic marketing and strategic operations.Strategic advisory work was performed for variety of life science tools, diagnostics, medical devices, specialty pharmaceuticals, biopharmaceuticals, biosimilars, hospital logistics and workflow solution companies, an academic non-profit organization, and both venture capital and private equity funds.
-
PresidentHawthorne Advisors, Inc. Apr 1999 - Jun 2010Strategic advisory work for life science company management teams, Boards of Directors, and investors. Also served as "contract operating partner"/interim executive for the life science investment community at these 5 companies:--PRESIDENT, CEO & BOARD MEMBER at Repromedix Corporation (diagnostic lab services, 2006)Delivered record operating performance in only three quarters: 1-Doctors Placing Orders: 39% increase over prior year, to highest quarterly number in company’s 12-year history2-New Doctors Placing Orders: 119% increase over prior year, with all 3 quarters being highest quarterly numbers ever3-Lab Specimens Tested: 40% increase over prior year, to third-highest quarter everDesigned novel Innovation Hub growth strategy: Reached understandings with female infertility clinicians affiliated with Harvard, Stanford, UCLA, USC, OHSU, WashU as well as reproductive urologists at UCSF, Whitehead, Brown, BU – yielding >25 clinical study sites and forming the first-ever male and female clinical study platforms for testing new infertility diagnostic technologiesGenerated $8 million financing term sheet--PRESIDENT, CEO & BOARD MEMBER at Ardais Corporation (software and services-based translational medicine solutions company, 2003-2005)Acquired by Gulfstream Bio--PRESIDENT, CEO & BOARD MEMBER at BioTransplant Incorporated (biopharmaceuticals, 2002-2003)After clinical trial failure of lead compound, Chapter 11 filing paid creditors 100 cents on the dollar, plus interest--GENERAL MANAGER at $30 million Custom Primers division of Invitrogen (life science tools, 2001-2002)Record performance improvements called out by CEO during his quarterly Wall Street call--COO at QSR (healthcare IT services, with medical billing business unit, 1999-2001)Strategic advisory work was performed for variety of specialty pharmaceuticals, home healthcare services, generic pharmaceuticals, healthcare staffing services, medical devices, and diagnostics companies.
-
Partner & Chief Financial OfficerAmpersand Ventures Jun 1997 - Apr 1999Served as:--COO at V. I. Technologies (VITEX) (biologics portfolio company, 1997-1998). Company achievements during tenure or within 3 months of departure: Successful FDA inspection. Successful product launch. $45 million IPO at valuation equal to 4X the cost basis 3 years after investment. Company achievements during subsequent 6 months: Revenue increased from $14 million to $45 million annualized run rate. Turned profitable for 2 most recent quarters. Became cash flow positive after being within 5 months of cash cliff upon my arrival at company.--BOARD MEMBER at Protient (specialty foods portfolio company, 1998-1999).
-
Chief Financial OfficerVarious Companies 1978 - 1997Greenwich, Ct, UsHeld progressively more responsible financial management positions, culminating in 3 CFO roles between 1989-1997:--Biocircuits Corporation, Sunnyvale, CA (diagnostics company- technology eventually acquired by Becton Dickinson) (VICE PRESIDENT & CFO, 1991-1997) Venture capital nvestors included: Venrock, Sprout, Burr Egan Deleage, Weiss Peck & Greer, Walden. Bankers: H&Q, Vector, Oppenheimer.--Oclassen Pharmaceuticals Inc., San Rafael, CA (specialty pharmaceuticals company - company eventually acquired by Watson Pharmaceuticals) (VICE PRESIDENT & CFO, 1990)--Genelabs Technologies Inc., Redwood City, CA (biopharmaceuticals company - company eventually acquired by GSK) (DIRECTOR OF FINANCE, then CFO) (1985-1990)--Syntex Corporation, Palo Alto, CA & Phoenix, AZ ($800 million branded pharmaceuticals company) (SENIOR FINANCIAL ANALYST in Corporate Planning) (FINANCIAL PLANNING MANAGER and then DIVISION CONTROLLER in $40 million ophthalmics device division) (1983-1985)--ARCO, Los Angeles, CA (FINANCIAL ANALYST I, then FINANCIAL ANALYST II, and then SENIOR FINANCIAL ANALYST in Corporate Finance Group within Treasury Department of $26 billion oil & gas company, 1981-1983)--ARAMCO, Dhahran, Saudi Arabia (SUMMER CONSULTANT, Maintenance Planning Department of oil & gas company, 1981)--Morgan Guaranty Bank, New York, NY (SUMMER INTERN, Petroleum Department, 1980)--Westinghouse Electric Corporation, Sunnyvale, CA (FINANCIAL PLANNER in Program Management department of $90 million Marine Division, 1978-1979) In less than eighteen months, led successful turnaround to 9% profitability for $5 million/year product line after years of it losing money.
Donald B. Hawthorne Skills
Donald B. Hawthorne Education Details
-
Stanford University Graduate School Of BusinessMaster Of Business Administration - Mba -
Harvey Mudd CollegeMathematics
Frequently Asked Questions about Donald B. Hawthorne
What company does Donald B. Hawthorne work for?
Donald B. Hawthorne works for Gtm® Hawthorne, Inc.
What is Donald B. Hawthorne's role at the current company?
Donald B. Hawthorne's current role is Helping CEOs and their C-suite colleagues Get GTM® Right so they can build companies for growth. Serve as peer-level-partner go-to-market strategy advisor, drawing on my 12 C-suite roles (CEO-6/COO-2/CFO-4)..
What is Donald B. Hawthorne's email address?
Donald B. Hawthorne's email address is do****@****grp.com
What is Donald B. Hawthorne's direct phone number?
Donald B. Hawthorne's direct phone number is +161733*****
What schools did Donald B. Hawthorne attend?
Donald B. Hawthorne attended Stanford University Graduate School Of Business, Harvey Mudd College.
What skills is Donald B. Hawthorne known for?
Donald B. Hawthorne has skills like Strategy, Medical Devices, Start Ups, Pharmaceutical Industry, Venture Capital, Lifesciences, Executive Management, Private Equity, Management, Mergers And Acquisitions, Entrepreneurship, Business Strategy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial